{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:02:22Z","timestamp":1779926542683,"version":"3.53.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lpm.2025.104331","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T23:37:57Z","timestamp":1763854677000},"page":"104331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sicca induced by immune checkpoint inhibitors"],"prefix":"10.1016","volume":"55","author":[{"given":"Rakiba","family":"Belkhir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-7892","authenticated-orcid":false,"given":"Marjolaine","family":"Gosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Bitoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lazure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6809-0733","authenticated-orcid":false,"given":"Gaetane","family":"Nocturne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.lpm.2025.104331_bib0001","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.lpm.2025.104331_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.lpm.2025.104331_bib0003","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.lpm.2025.104331_bib0004","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/odi.14000","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"28","author":"Harris","year":"2022","journal-title":"Oral Dis"},{"issue":"10027","key":"10.1016\/j.lpm.2025.104331_bib0005","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.lpm.2025.104331_bib0006","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.lpm.2025.104331_bib0007","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with Immune checkpoint inhibitor therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.lpm.2025.104331_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102892","article-title":"Tumors, tumor therapies, autoimmunity and the eye","volume":"20","author":"Wildner","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.lpm.2025.104331_bib0009","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajo.2019.02.012","article-title":"Prevalence and clinical patterns of ocular complications associated with Anti-PD-1\/PD-L1 anticancer immunotherapy","volume":"202","author":"Bitton","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.lpm.2025.104331_bib0010","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2020.11.001","article-title":"Ophthalmic immune-related adverse events after anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry","volume":"128","author":"Sun","year":"2021","journal-title":"Ophthalmology"},{"issue":"23","key":"10.1016\/j.lpm.2025.104331_bib0011","article-title":"Ocular surface toxicities associated with modern anticancer therapies","volume":"S0039-6257","author":"Boucher","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.lpm.2025.104331_bib0012","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jtos.2021.02.004","article-title":"Ocular surface disease associated with immune checkpoint inhibitor therapy","volume":"20","author":"Park","year":"2021","journal-title":"Ocul Surf"},{"key":"10.1016\/j.lpm.2025.104331_bib0013","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ajo.2024.08.044","article-title":"Ophthalmic immune-related adverse events and association with survival: results from a real-world database","volume":"268","author":"Quiruz","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.lpm.2025.104331_bib0014","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/08820538.2023.2204931","article-title":"Real life impact of dry eye disease","volume":"38","author":"Cutrupi","year":"2023","journal-title":"Semin Ophthalmol"},{"issue":"4","key":"10.1016\/j.lpm.2025.104331_bib0015","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/bjophthalmol-2020-317473","article-title":"Assessment of patient burden from dry eye disease using a combination of five visual analogue scales and a radar graph: a pilot study of the PENTASCORE","volume":"106","author":"Labetoulle","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.lpm.2025.104331_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-067007","article-title":"Patient-reported burden and overall impact of dry eye disease across eight European countries: a cross-sectional web-based survey","volume":"13","author":"Boboridis","year":"2023","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.lpm.2025.104331_bib0017","first-page":"114","article-title":"Sicca\/Sj\u00f6gren\u2019s syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)","volume":"37","author":"Ramos-Casals","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.lpm.2025.104331_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105426","article-title":"Associations between ocular and extra-ocular assessment in primary Sj\u00f6gren\u2019s syndrome","volume":"89","author":"Da Cunha","year":"2022","journal-title":"Joint Bone Spine"},{"issue":"9","key":"10.1016\/j.lpm.2025.104331_bib0019","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nrrheum.2013.110","article-title":"Advances in understanding the pathogenesis of primary Sj\u00f6gren\u2019s syndrome","volume":"9","author":"Nocturne","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"10.1016\/j.lpm.2025.104331_bib0020","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren\u2019s syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2025.104331_bib0021","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaut.2009.10.004","article-title":"Characteristics of the minor salivary gland infiltrates in Sj\u00f6gren\u2019s syndrome","volume":"34","author":"Christodoulou","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.lpm.2025.104331_bib0022","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3389\/fonc.2020.00420","article-title":"Lack of conventional acinar cells in parotid salivary gland of patient taking an Anti-PD-L1 immune checkpoint inhibitor","volume":"10","author":"Pringle","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.lpm.2025.104331_bib0023","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell Death-Ligand 1 agents: a single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.lpm.2025.104331_bib0024","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.40397","article-title":"Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience","volume":"70","author":"Richter","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.lpm.2025.104331_bib0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.lpm.2025.104331_bib0026","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.lpm.2025.104331_bib0027","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.oraloncology.2007.01.015","article-title":"Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction","volume":"44","author":"Jensen","year":"2008","journal-title":"Oral Oncol."},{"issue":"1","key":"10.1016\/j.lpm.2025.104331_bib0028","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1038\/s41598-020-59078-0","article-title":"Patients with non-Sj\u00f6gren\u2019s sicca report poorer general and oral health-related quality of life than patients with Sj\u00f6gren\u2019s syndrome: a cross-sectional study","volume":"10","author":"Tashbayev","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.lpm.2025.104331_bib0029","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ajo.2020.05.043","article-title":"Ocular manifestations and burden related to Sj\u00f6gren syndrome: results of a patient survey","volume":"219","author":"Saldanha","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.lpm.2025.104331_bib0030","first-page":"1259","article-title":"Validation of the Sicca Symptoms Inventory for clinical studies of Sj\u00f6gren\u2019s syndrome","volume":"30","author":"Bowman","year":"2003","journal-title":"J. Rheumatol."},{"issue":"2","key":"10.1016\/j.lpm.2025.104331_bib0031","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/rheumatology\/ken426","article-title":"Patient-reported outcomes in primary Sjogren\u2019s syndrome: comparison of the long and short versions of the Profile of Fatigue and Discomfort\u2013Sicca Symptoms Inventory","volume":"48","author":"Bowman","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.lpm.2025.104331_bib0032","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.lpm.2025.104331_bib0033","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/rheumatology\/kev385","article-title":"Is salivary gland ultrasonography a useful tool in Sj\u00f6gren\u2019s syndrome? A systematic review","volume":"55","author":"Jousse-Joulin","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.lpm.2025.104331_bib0034","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11282-020-00480-9","article-title":"Radiological imaging features of the salivary glands in xerostomia induced by an immune checkpoint inhibitor","volume":"37","author":"Katsura","year":"2021","journal-title":"Oral Radiol"},{"issue":"3","key":"10.1016\/j.lpm.2025.104331_bib0035","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/cancers14030792","article-title":"Oral immune-related adverse events caused by immune checkpoint inhibitors: salivary gland dysfunction and mucosal diseases","volume":"14","author":"Yura","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.lpm.2025.104331_bib0036","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0161-6420(00)00538-8","article-title":"Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs","volume":"108","author":"Guidera","year":"2001","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.lpm.2025.104331_bib0037","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1136\/bjophthalmol-2019-314859","article-title":"Blood derived treatment from two allogeneic sources for severe dry eye associated to keratopathy: a multicentre randomised cross over clinical trial","volume":"104","author":"Campos","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.lpm.2025.104331_bib0038","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jtos.2021.09.003","article-title":"Combined therapy of ocular surface disease with plasma rich in growth factors and scleral contact lenses","volume":"23","author":"Wang","year":"2022","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.lpm.2025.104331_bib0039","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/08820538.2021.1966059","article-title":"Systemic immunosuppression in cornea and ocular surface disorders: a ready reckoner for ophthalmologists","volume":"37","author":"Kate","year":"2022","journal-title":"Semin Ophthalmol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498225000648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498225000648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:07:17Z","timestamp":1779923237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498225000648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0755498225000648"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2025.104331","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sicca induced by immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2025.104331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104331"}}